Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241217 | 1.00 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL319610 | 1.00 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7238858 | 0.98 | CCR2 (0.71) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7238979 | 0.94 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL20581684 | 0.94 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL320179 | 0.94 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3936733 | 0.86 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL14778920 | 0.86 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7383773 | 0.86 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL6555302 | 0.86 | CCR2 (0.64) | CCR2RAB9AALDH1A1NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230002422-A1 | REACTION AGENT FOR AMIDE REACTIONS AND AMIDE COMPOUND PRODUCTION METHOD USING SAME | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| EP-3761984-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200370057-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10745705-B2 | Ribosome-mediated incorporation of peptides and peptidomimetics | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3247801-A1 | RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118877-A1 | RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9346852-B2 | Substituted adipic acid amides and uses thereof | BRISTOL-MYERS SCUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012125622-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2029581-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007126871-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2004092168-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002422-A1 | REACTION AGENT FOR AMIDE REACTIONS AND AMIDE COMPOUND PRODUCTION METHOD USING SAME | NAAA, NOTUM, ASNS | CCR2 3584/4885RAB9A 1084/4885ALDH1A1 738/4885 |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, FABP4, SLC2A3 | CCR2 2488/4885RAB9A 2047/4885ALDH1A1 723/4885 |
| US-20200370057-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | CCR2 3540/4885RAB9A 3287/4885ALDH1A1 4835/4885 |
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | CCR2 3540/4885RAB9A 3287/4885ALDH1A1 4835/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CCR2 4758/4885RAB9A 1362/4885ALDH1A1 1320/4885 |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | CCR2 3701/4885RAB9A 3235/4885ALDH1A1 2926/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | CCR2 3701/4885RAB9A 3235/4885ALDH1A1 2926/4885 |
| US-10745705-B2 | Ribosome-mediated incorporation of peptides and peptidomimetics | NPEPPS, DNPEP, AARS1 | CCR2 3540/4885RAB9A 3287/4885ALDH1A1 4835/4885 |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | FABP1, AADAT, FABP6 | CCR2 1378/4885RAB9A 3637/4885ALDH1A1 1195/4885 |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | NPY4R, ADIPOR1, NPY1R | CCR2 321/4885RAB9A 2511/4885ALDH1A1 1872/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | CCR2 1680/4885RAB9A 258/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.